{"id":"8b3f60356f9e","type":"article","url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","title":"2018 AHA/ACC cholesterolrichtlijn: JACC volledig rapport","title_en":"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2018.11.003","source_url":"https://doi.org/10.1016/j.jacc.2018.11.003","authors":["Scott M Grundy","Neil J Stone","Alison L Bailey","Craig Beam","Kim K Birtcher","Roger S Blumenthal","Lynne T Braun","Sarah de Ferranti","Joseph Faiella-Tommasino","Daniel E Forman","Ronald Goldberg","Paul A Heidenreich","Mark A Hlatky","Daniel W Jones","Donald Lloyd-Jones","Nuria Lopez-Pajares","Chiadi E Ndumele","Carl E Orringer","Carmen A Peralta","Joseph J Saseen","Sidney C Smith","Laurence Sperling","Salim S Virani","Joseph Yeboah"],"significance":9,"published":"2019-06-25","source_date":"2019-06-25","image":"","kennis":[],"congress":"","summary_en":"JACC publication of the full 2018 AHA/ACC blood cholesterol guideline, providing comprehensive recommendations on risk assessment, statin therapy intensity, and nonstatin therapies including ezetimibe and PCSK9 inhibitors for cardiovascular risk reduction.","created":"2026-07-03T10:28:00Z","updated":"2026-07-03T13:27:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"JACC-publicatie van het volledige rapport van de 2018 AHA/ACC cholesterolrichtlijn.","abstract_original":""}